1. Iroquois Capital Issues Statement In Response To Recent Actions By The Pharmacyte Biotech Board Of Directors

    Iroquois Capital Issues Statement In Response To Recent Actions By The Pharmacyte Biotech Board Of Directors

    NEW YORK , July 5, Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), one of the largest stockholders of PharmaCyte Biotech, Inc. ("PharmaCyte", "PMCB" or the "Company") (NASDAQ: PMCB ) with beneficial ownership of approximately 6.3% of the outstanding common stock of the Company, today provided the following statement in response to certain actions recently taken by the Company...

    Read Full Article

    Login to comment.

  1. Categories

    1. BoardProspects Features:

      Board Recruitment Publication, BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, Competitor Corner, In the News, Member Report, Partner Publications, Question of The Week, Sponsored Content
  2. Topics Mentioned

  3. Authors